CA1214391A - Long-acting matrix tablet formulations - Google Patents

Long-acting matrix tablet formulations

Info

Publication number
CA1214391A
CA1214391A CA000434335A CA434335A CA1214391A CA 1214391 A CA1214391 A CA 1214391A CA 000434335 A CA000434335 A CA 000434335A CA 434335 A CA434335 A CA 434335A CA 1214391 A CA1214391 A CA 1214391A
Authority
CA
Canada
Prior art keywords
tablet
weight
acid
amount
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000434335A
Other languages
English (en)
French (fr)
Inventor
Morgan L. Beatty
Wayne A. Boettner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of CA1214391A publication Critical patent/CA1214391A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CA000434335A 1982-08-12 1983-08-10 Long-acting matrix tablet formulations Expired CA1214391A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/407,511 US4704284A (en) 1982-08-12 1982-08-12 Long-acting matrix tablet formulations
US407,511 1982-08-12

Publications (1)

Publication Number Publication Date
CA1214391A true CA1214391A (en) 1986-11-25

Family

ID=23612384

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000434335A Expired CA1214391A (en) 1982-08-12 1983-08-10 Long-acting matrix tablet formulations

Country Status (17)

Country Link
US (1) US4704284A (ko)
EP (1) EP0103387A3 (ko)
JP (1) JPS5948415A (ko)
KR (1) KR860000840B1 (ko)
AU (1) AU546249B2 (ko)
CA (1) CA1214391A (ko)
DK (1) DK365883A (ko)
EG (1) EG16065A (ko)
ES (1) ES524892A0 (ko)
FI (1) FI82186C (ko)
GR (1) GR78921B (ko)
GT (1) GT198303076A (ko)
NO (1) NO169818C (ko)
NZ (1) NZ205205A (ko)
PH (1) PH18211A (ko)
PT (1) PT77185B (ko)
ZA (1) ZA835900B (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0729927B2 (ja) * 1983-04-09 1995-04-05 日研化学株式会社 テオフィリン徐放性製剤
IE58246B1 (en) * 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US5188840A (en) * 1985-09-26 1993-02-23 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
US4837032A (en) * 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
US4820523A (en) * 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
JPH0776172B2 (ja) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 マトリツクス錠
US4917892A (en) * 1988-06-28 1990-04-17 Temple University Encapsulated topical delivery system
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5364646A (en) * 1990-01-10 1994-11-15 Dr. Karl Thomae Gmbh Oral pharmaceutical forms of pimobendan
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
MX9300110A (es) * 1992-01-13 1994-07-29 Gerhard Gergely Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
US20070082918A1 (en) * 1993-11-02 2007-04-12 Naftchi N E Neurologically active compounds and compounds with multiple activities
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
DE19631084A1 (de) * 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut
US6028929A (en) * 1997-11-14 2000-02-22 Tellabs Operations, Inc. Echo canceller employing dual-H architecture having improved non-linear echo path detection
US20020106408A1 (en) * 2000-12-01 2002-08-08 Johnatan Bacon Prolamin-based sustained-release compositions and delayed-onset compositions
PT1480679E (pt) * 2002-02-26 2007-07-18 Astrazeneca Ab Fórmulação farmacêutica de iressa compreendendo um derivado de celulose solúvel em água
US20060093661A1 (en) * 2002-05-07 2006-05-04 Kapac, Llc Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
KR101152470B1 (ko) 2003-08-13 2012-06-01 바이오콘 리미티드 치료제용 마이크로-입자 지방산 염 고형 투약 제형
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
ES2924478T3 (es) 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos
CN105377235A (zh) 2013-07-19 2016-03-02 勃林格殷格翰动物保健有限公司 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
BR112016011111B1 (pt) 2013-12-04 2022-11-16 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas aprimoradas de pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2793979A (en) * 1953-03-30 1957-05-28 Smith Kline French Lab Method of making a sustained release pharmaceutical tablet and product of the method
US2953497A (en) * 1953-06-03 1960-09-20 Howard A Press Therapeutic tablets
US3044938A (en) * 1955-07-01 1962-07-17 Sandoz Chemical Works Inc Sustained action pharmaceutical tablets
US2809917A (en) * 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical tablets
NL109293C (ko) * 1955-12-22
US3039933A (en) * 1957-10-07 1962-06-19 Premo Pharmaceutical Lab Inc Ethyl cellulose-polyethylene glycol tablet matrix
US2993836A (en) * 1958-02-20 1961-07-25 Dow Chemical Co Sustained release tablets
US2956926A (en) * 1958-09-23 1960-10-18 American Cyanamid Co Coated citric acid particles
US2987445A (en) * 1958-10-10 1961-06-06 Rohm & Haas Drug composition
US3087860A (en) * 1958-12-19 1963-04-30 Abbott Lab Method of prolonging release of drug from a precompressed solid carrier
US2951792A (en) * 1959-11-18 1960-09-06 Smith Kline French Lab Sustained release pharmaceutical tablets
NL113366C (ko) * 1961-02-24
US3115441A (en) * 1962-06-06 1963-12-24 Victor M Hermelin Timed release pharmaceutical preparations and method of making the same
US3336200A (en) * 1963-05-28 1967-08-15 Warner Lambert Pharmaceutical Tablet structure
NL297631A (ko) * 1963-06-03
US3400197A (en) * 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
FR1545612A (fr) * 1967-06-15 1968-11-15 Dausse Lab Procédé de fabrication de comprimés
US3577514A (en) * 1968-06-10 1971-05-04 Pfizer Sustained release pharmaceutical tablets
US3608063A (en) * 1969-08-15 1971-09-21 Gilbert S Banker Molecular drug entrapment process and compositions
US3632739A (en) * 1969-12-29 1972-01-04 Sandoz Ag Solid sustained release pharmaceutical preparation
US3669968A (en) * 1970-05-21 1972-06-13 Pfizer Trialkoxy quinazolines
US3906086A (en) * 1971-07-19 1975-09-16 Richard G Powers Timed-release aspirin
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US4012498A (en) * 1974-03-27 1977-03-15 Sandoz, Inc. Sustained release tablet formulations
US3939259A (en) * 1974-05-24 1976-02-17 Anthony Pescetti Coating composition and therapeutic preparation incorporating same
US3978203A (en) * 1974-07-12 1976-08-31 Dynatech Corporation Sustained release of pharmaceuticals from polyester matrices
US4171363A (en) * 1977-02-22 1979-10-16 Bristol-Myers Company 1,2,3-Thiadiazole process
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
US4130647A (en) * 1977-07-08 1978-12-19 Pfizer Inc. Methods for treating congestive heart failure and ischemic heart disease
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
JPS55153715A (en) * 1979-05-18 1980-11-29 Nikken Kagaku Kk Prolonged granule of theophylline
US4361545A (en) * 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
JPS5649314A (en) * 1979-07-05 1981-05-02 Yamanouchi Pharmaceut Co Ltd Lasting pharmaceutical composition having prolonged action and its preparation
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4248856A (en) * 1979-07-10 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
JPS56122311A (en) * 1980-02-29 1981-09-25 Eisai Co Ltd Lasting theophylline pharmaceutical composition

Also Published As

Publication number Publication date
PT77185A (en) 1983-09-01
JPS5948415A (ja) 1984-03-19
NZ205205A (en) 1986-06-11
EP0103387A2 (en) 1984-03-21
EP0103387A3 (en) 1984-12-12
FI82186C (fi) 1991-02-11
NO832883L (no) 1984-02-13
DK365883A (da) 1984-02-13
ES8502333A1 (es) 1985-01-01
NO169818B (no) 1992-05-04
PH18211A (en) 1985-04-30
ES524892A0 (es) 1985-01-01
AU1788683A (en) 1984-02-16
FI832895A (fi) 1984-02-13
ZA835900B (en) 1985-03-27
GR78921B (ko) 1984-10-02
KR840005661A (ko) 1984-11-15
US4704284A (en) 1987-11-03
EG16065A (en) 1986-12-30
DK365883D0 (da) 1983-08-11
NO169818C (no) 1992-08-12
KR860000840B1 (ko) 1986-07-09
FI82186B (fi) 1990-10-31
FI832895A0 (fi) 1983-08-11
PT77185B (en) 1986-07-11
AU546249B2 (en) 1985-08-22
GT198303076A (es) 1985-01-30

Similar Documents

Publication Publication Date Title
CA1214391A (en) Long-acting matrix tablet formulations
US4765990A (en) Sustained-release nifedipine preparation
CA1315202C (en) Oral sustained release acetaminophen formulation and process
EP0290168B1 (en) Ibuprofen sustained release matrix and process
KR950007204B1 (ko) 압축 성형 제제
US3965256A (en) Slow release pharmaceutical compositions
US4235870A (en) Slow release pharmaceutical compositions
US3344029A (en) Sustained release composition
US4650664A (en) Oral mopidamol preparation
US5030455A (en) Sustained-release drug preparation
IE57954B1 (en) Storage-stable,quick disintegrating tablets
WO2001082895A2 (en) Guaifenesin sustained release formulation and tablets
AU2001255680A1 (en) Guaifenesin sustained release formulation and tablets
EP0221732A2 (en) Sustained release tablets
SI8710406A (en) Sustained release tablets on the basis of high molecular weight hydroxypropylmethylcellulose and a process for their manufacture
JPS63267720A (ja) エモルフアゾンの徐放性製剤
JPS625915A (ja) 塩酸ジルチアゼム徐放性製剤及びその製法
JPH02223522A (ja) Ｎｂ―８１８の易吸収性製剤
JPH11286438A (ja) 徐放性製剤
JP2521461B2 (ja) 持続性錠剤
JPS61112012A (ja) 持続放出性製剤の製造法
JPH09263537A (ja) 徐放性塩酸ニカルジピン製剤

Legal Events

Date Code Title Description
MKEX Expiry